Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2026
Mar 30, 2026
9:05 AM EDT
Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 trial, will be presenting at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, being held April 10 – 13, 2026, in…
Mar 12, 2026
10:38 AM EDT
Its Chairman and CEO, Dr. Amit Kumar, is featured on today's Water Tower Research Healthcare Happenings podcast.
Mar 09, 2026
8:30 AM EDT
The Korean Ministry of Intellectual Property (MOIP) has issued a Notice of Allowance for a new patent related to Anixa's breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment…
Mar 02, 2026
9:10 AM EST
It will host its 2026 Annual Meeting of Stockholders (the "Meeting") on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. The Meeting will be open to all interested parties, including non-stockholders.
Feb 23, 2026
8:55 AM EST
Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine and the co-inventor of Anixa's CAR-T technology, will be a keynote speaker at the South Carolina Clinical & Translational Research (SCTR) Institute 2026 Retreat: Cell-Based…
Feb 09, 2026
8:00 AM EST
An update on patient outcomes observed in its ongoing Phase 1 ovarian cancer CAR-T clinical trial, following regulatory approval of a protocol amendment that enables substantial dose escalation.
Feb 02, 2026
9:00 AM EST
The United States Adopted Names (USAN) Council approved "liraltagene autoleucel" for the non-proprietary name of the Company's novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. This U.S.
Jan 27, 2026
8:30 AM EST
The Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment and…
2025
Dec 15, 2025
8:45 AM EST
It has completed the transfer of the Investigational New Drug application ("IND") for its breast cancer vaccine from Cleveland Clinic. Anixa is now the trial sponsor for future development of its breast cancer vaccine. The transfer of the IND is a natural and planned step in the progresson of the vaccine's development.
Dec 11, 2025
6:02 PM EST
The presentation of final data from the Phase 1 clinical trial of its investigational breast cancer vaccine ( NCT04674306 ) at the 2025 San Antonio Breast Cancer Symposium (SABCS). The trial was conducted in collaboration with Cleveland Clinic and funded by a grant from the U.S. Department of Defense.
Dec 10, 2025
9:00 AM EST
Its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Monday, December 15, 2025, at 1:00pm ET.
Nov 17, 2025
8:15 AM EST
The International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) approved "liraltagene autoleucel" for the non-proprietary name of the Company's novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Nov 12, 2025
9:00 AM EST
The United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,472,205 on November 18, 2025, covering key aspects of the Company's breast cancer vaccine technology.
Nov 10, 2025
10:30 AM EST
Its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Tuesday, November 11, 2025, at 11:00am PT.
Nov 05, 2025
8:55 AM EST
It has executed a data transfer agreement ("DTA") with Cleveland Clinic, as a key step in the process of transferring the breast cancer vaccine clinical trial data and sponsorship to Anixa for future clinical development.
Oct 23, 2025
8:45 AM EDT
It will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City.
Oct 20, 2025
8:25 AM EDT
The Chinese National Intellectual Property Administration (CNIPA) has issued Patent Number ZL2020800215666, covering key aspects of the Company's breast cancer vaccine technology.
Oct 07, 2025
8:30 AM EDT
The completion of the final patient visit in its breast cancer vaccine clinical trial. This novel vaccine, invented at Cleveland Clinic, is being developed in partnership with Cleveland Clinic, and the Phase 1 trial is fully funded by a grant from the U.S. Department of Defense.
Sep 08, 2025
8:00 AM EDT
It has completed dosing of the fourth cohort in its ongoing Phase 1 clinical trial ( ClinicalTrials.gov NCT05316129 ) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt").
Sep 02, 2025
8:54 AM EDT
The time of management's presentation at the H.C. Wainwright 27 th Annual Global Investment Conference, being held September 8 th – 10 th , 2025 in New York City , has been changed to 10:30 AM ET on September 9 .
